{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
NewAmsterdam Pharma Co. NV
Is NewAmsterdam Pharma Co. NV technically bullish or bearish?
As of October 31, 2025, NewAmsterdam Pharma Co. NV shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, but mixed signals from RSI and Dow Theory indicate some weakness.
Is NewAmsterdam Pharma Co. NV technically bullish or bearish?
As of October 31, 2025, NewAmsterdam Pharma Co. NV's trend is mildly bullish, supported by weekly MACD and Bollinger Bands, despite bearish weekly and monthly RSI readings, while significantly outperforming the S&P 500 with a 1-year return of 122.97%.
Is NewAmsterdam Pharma Co. NV technically bullish or bearish?
As of October 31, 2025, NewAmsterdam Pharma Co. NV shows a mildly bullish trend, supported by strong momentum indicators and outperformance against the S&P 500, despite some bearish signals in the RSI and KST.
NewAmsterdam Pharma Hits Day High with 8.05% Surge, Strong Intraday Performance
NewAmsterdam Pharma Co. NV has seen notable stock performance, gaining 8.05% on October 30, 2025, and achieving a 36.15% increase over the past month. The company reported significant growth in net sales and maintains 100% institutional holdings, despite facing challenges with negative EBITDA and pre-tax losses.
NewAmsterdam Pharma Co. NV Hits New 52-Week High of USD 41.39
NewAmsterdam Pharma Co. NV has achieved a new 52-week high, reflecting a remarkable performance with a significant increase over the past year. The company, with a market capitalization of USD 2,826 million, faces challenges such as negative return on equity and a notable debt-to-equity ratio, yet continues to attract attention.
NewAmsterdam Pharma Hits New 52-Week High of $39.76, Up 88.77%
NewAmsterdam Pharma Co. NV achieved a new 52-week high of USD 39.76 on October 13, 2025, reflecting an 88.77% increase over the past year. The company, with a market cap of USD 2,826 million, remains unprofitable, highlighting the volatility and potential in the small-cap pharmaceuticals sector.
NewAmsterdam Pharma Hits New 52-Week High of $34.62
NewAmsterdam Pharma Co. NV achieved a new 52-week high of USD 34.62 on October 6, 2025, reflecting its notable performance in the Pharmaceuticals & Biotechnology sector. The company, with a market capitalization of USD 2,826 million, has experienced significant stock fluctuations over the past year.
NewAmsterdam Pharma Co. Hits New 52-Week High of USD 31.81
NewAmsterdam Pharma Co. NV achieved a new 52-week high of USD 31.81 on October 3, 2025, reflecting strong performance in the pharmaceuticals sector with a 55.84% increase over the past year. The company, with a market cap of USD 2,826 million, remains unprofitable and does not offer dividends.
NewAmsterdam Pharma Co. NV Hits New 52-Week High at $29.66
NewAmsterdam Pharma Co. NV achieved a new 52-week high of USD 29.66 on October 1, 2025, reflecting strong performance over the past year. The company, with a market capitalization of USD 2,826 million, faces challenges in profitability, evidenced by a negative return on equity and unique financial structure.
NewAmsterdam Pharma Co. NV Hits New 52-Week High of $28.61
NewAmsterdam Pharma Co. NV has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector with a notable annual increase. The company, with a market capitalization of USD 2,826 million, continues to navigate challenges, including a loss-making position and a unique financial structure.
NewAmsterdam Pharma Stock Hits Day High with 8.41% Surge
NewAmsterdam Pharma Co. NV has seen notable stock performance, with significant gains over various timeframes, including a 13.14% increase in the past month. The company reported a remarkable 740.06% rise in net sales, despite facing challenges with negative EBITDA and a pre-tax loss. Institutional ownership remains strong at 100%.
Is NewAmsterdam Pharma Co. NV technically bullish or bearish?
As of September 2, 2025, NewAmsterdam Pharma Co. NV has shifted to a bullish trend, supported by positive indicators like a bullish MACD, Bollinger Bands, and moving averages, with a 67.59% return over the past year compared to the S&P 500's 17.14%.
NewAmsterdam Pharma Soars 9.15% to Hit Intraday High of $26.75
NewAmsterdam Pharma Co. NV's stock surged significantly on September 18, 2025, reaching an intraday high amid strong market activity. The company reported a remarkable 740.06% growth in net sales, despite a pre-tax loss. Institutional holdings have reached 100%, reflecting strong investor confidence in the firm.
Is NewAmsterdam Pharma Co. NV overvalued or undervalued?
As of May 8, 2024, NewAmsterdam Pharma Co. NV is considered risky and overvalued due to negative earnings and poor return metrics, with a Price to Book Value of 2.91 and significantly negative EV to EBIT and EV to EBITDA ratios, while its stock has underperformed the S&P 500 with a year-to-date return of -29.14%.
Is NewAmsterdam Pharma Co. NV technically bullish or bearish?
As of May 10, 2024, the trend is mildly bullish due to positive weekly MACD and KST indicators, but caution is advised due to bearish daily moving averages and mixed signals from Bollinger Bands and Dow Theory.
What does NewAmsterdam Pharma Co. NV do?
NewAmsterdam Pharma Co. NV is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $40 million as of March 2025. It has a market cap of approximately $2.08 billion and key metrics indicate it is currently loss-making with no dividend yield.
How big is NewAmsterdam Pharma Co. NV?
As of Jun 18, NewAmsterdam Pharma Co. NV has a market capitalization of 2,075.88 million, with net sales of 47.14 million and a net profit of -187.37 million over the last four quarters. Shareholder's funds are 757.50 million, and total assets are 864.62 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
